Bladder Cancer

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility July 10, 2026

Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making. July 10, 2026

Diagnosis, Evaluation, and Management of Patients with Non-Muscle Invasive Bladder Cancer - Beyond the Abstract July 9, 2026

Beyond the bladder: case series of Mycobacterium bovis bacillus Calmette-Guérin infections following intravesical instillation. July 9, 2026

Outcomes of Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A Real-World Experience - Beyond the Abstract July 8, 2026

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study. July 8, 2026

Durable Responses and Cystectomy Avoidance with IL-15 Receptor Agonist NAI plus BCG In BCG-Unresponsive NMIBC with Carcinoma In Situ +/- Papillary Disease. July 7, 2026

Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC). July 6, 2026

Predictors of residual tumour and recurrence in high-grade NMIBC: insights from a multicenter re-TURBT cohort. July 6, 2026

Assessing Human Epidermal Growth Factor Receptor 2 in Urothelial Carcinoma: Insights From Clinical Practice Into Scoring Criteria, Histologic Subtypes, and Genomic Characteristics Across Disease Sites. July 3, 2026

MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials. July 10, 2026

Impact of body mass index on outcomes after radical cystectomy: A retrospective Australian cohort study. July 10, 2026

Phase I first-in-human dose-escalation trial of a bladder cancer-specific nanoparticle in non-muscle-invasive bladder cancer. July 9, 2026

The impact of cachexia and sarcopenia in bladder cancer. July 9, 2026

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer. July 8, 2026

Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner. July 7, 2026

Outcomes of maintenance BCG versus gemcitabine/docetaxel following BCG induction in NMIBC. July 7, 2026

The role of microRNAs-23b and 27b in migration, invasion and proliferation of T24 bladder cancer cells. July 6, 2026

A Quantitative Modification of VI-RADS for Bladder Cancer at the Ureteral Orifice: A Reader Study on MRI With Varying Experience Levels. July 3, 2026

Role of Postoperative Radiation Therapy After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis. July 3, 2026

Page 1 of 606